Hainan Poly Pharm Co Ltd (300630) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hainan Poly Pharm Co Ltd (300630) has a cash flow conversion efficiency ratio of 0.015x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥44.82 Million ≈ $6.56 Million USD) by net assets (CN¥3.01 Billion ≈ $440.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hainan Poly Pharm Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2023)
This chart illustrates how Hainan Poly Pharm Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 300630 liabilities breakdown for a breakdown of total debt and financial obligations.
Hainan Poly Pharm Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hainan Poly Pharm Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tridomain Performance Materials PT
JK:TDPM
|
0.076x |
|
Lokman Hekim Engurusag Saglik Turizm Egitim Hizmetleri ve Insaat Taahhut AS
IS:LKMNH
|
-0.037x |
|
SAURASHTRA CEM B ORD (BSE)
NSE:SAURASHCEM
|
N/A |
|
WithTech Inc.
KQ:348350
|
-0.043x |
|
Hindustan Composites Limited
NSE:HINDCOMPOS
|
0.018x |
|
Lida Holdings Ltd
TW:4552
|
0.050x |
|
AEC SECURITIES
BK:BYD-R
|
N/A |
|
ANDRADA MINING LTD.
F:9IA
|
N/A |
Annual Cash Flow Conversion Efficiency for Hainan Poly Pharm Co Ltd (2016–2023)
The table below shows the annual cash flow conversion efficiency of Hainan Poly Pharm Co Ltd from 2016 to 2023. For the full company profile with market capitalisation and key ratios, see Hainan Poly Pharm Co Ltd (300630) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | CN¥2.91 Billion ≈ $425.27 Million |
CN¥112.72 Million ≈ $16.49 Million |
0.039x | -79.66% |
| 2022-12-31 | CN¥2.80 Billion ≈ $410.10 Million |
CN¥534.29 Million ≈ $78.18 Million |
0.191x | +208.59% |
| 2021-12-31 | CN¥2.54 Billion ≈ $371.94 Million |
CN¥157.03 Million ≈ $22.98 Million |
0.062x | -62.06% |
| 2020-12-31 | CN¥2.04 Billion ≈ $298.39 Million |
CN¥332.08 Million ≈ $48.59 Million |
0.163x | -13.35% |
| 2019-12-31 | CN¥1.15 Billion ≈ $167.69 Million |
CN¥215.37 Million ≈ $31.52 Million |
0.188x | +75.14% |
| 2018-12-31 | CN¥883.26 Million ≈ $129.25 Million |
CN¥94.79 Million ≈ $13.87 Million |
0.107x | -17.46% |
| 2017-12-31 | CN¥721.37 Million ≈ $105.56 Million |
CN¥93.79 Million ≈ $13.72 Million |
0.130x | -28.09% |
| 2016-12-31 | CN¥307.12 Million ≈ $44.94 Million |
CN¥55.53 Million ≈ $8.13 Million |
0.181x | -- |
About Hainan Poly Pharm Co Ltd
Hainan Poly Pharm. Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China and internationally. The company's dosage formulations comprise of tablets, capsules, granules, ointments, eye drops, pre-infusion, injection, lyophilization, and oral solutions. It also offers pharmaceutical preparations, active pharmaceutical ingredients, other raw materials, exc… Read more